Männel Barbara, Hübner Harald, Möller Dorothée, Gmeiner Peter
Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander University Erlangen-Nürnberg, Schuhstraße 19, 91052 Erlangen, Germany.
Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander University Erlangen-Nürnberg, Schuhstraße 19, 91052 Erlangen, Germany.
Bioorg Med Chem. 2017 Oct 15;25(20):5613-5628. doi: 10.1016/j.bmc.2017.08.037. Epub 2017 Aug 24.
β-Arrestin biased G protein-coupled receptor ligands represent important molecular probes and may increase favorable drug action and safety as novel therapeutics. Starting from recently discovered hydroxy-substituted heterocyclic piperazine scaffolds, we have developed a series of dopamine D receptor ligands with a pyrazolo[1,5-a]pyridine as secondary pharmacophore that is functionalized in position 3 by a formyl or hydroxyiminomethyl substituent. The ligands, especially the benzoxazinone 9d, were found to stimulate substantial β-arrestin-2 recruitment, while being nearly devoid of activity in a GTPγS binding assay. Investigating a new series of truncated analogs lacking a secondary pharmacophore, considerable β-arrestin-2 recruitment in the absence of G protein activation was found, when a 5-hydroxy-2H-benzo[b][1,4]oxazin-3(4H)-one was combined with an N-propyl-substituted 1,4-diazepane (15c). Although 15c displayed reduced potency compared to 9d, the dose-response curves indicate that a hydroxy-substituted heterocyclic primary pharmacophore is sufficient for the functionally selective activation of DR.
β-抑制蛋白偏向性G蛋白偶联受体配体是重要的分子探针,作为新型治疗药物可能会增强药物的有益作用并提高安全性。从最近发现的羟基取代的杂环哌嗪支架出发,我们开发了一系列以吡唑并[1,5-a]吡啶作为二级药效团的多巴胺D受体配体,该二级药效团在3位被甲酰基或羟基亚氨基甲基取代基官能化。发现这些配体,尤其是苯并恶嗪酮9d,能刺激大量β-抑制蛋白-2募集,而在GTPγS结合试验中几乎没有活性。研究一系列缺少二级药效团的截短类似物时,发现当5-羟基-2H-苯并[b][1,4]恶嗪-3(4H)-酮与N-丙基取代的1,4-二氮杂环庚烷(15c)结合时,在没有G蛋白激活的情况下也能引起相当程度的β-抑制蛋白-2募集。尽管15c与9d相比效价降低,但剂量反应曲线表明羟基取代的杂环一级药效团足以实现多巴胺受体的功能选择性激活。